Singapore
· Delayed Price · Currency is SGD Biolidics Statistics
Total Valuation
Biolidics has a market cap or net worth of SGD 23.67 million. The enterprise value is 25.94 million.
| Market Cap | 23.67M |
| Enterprise Value | 25.94M |
Important Dates
The last earnings date was Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biolidics has 1.69 billion shares outstanding. The number of shares has increased by 53.94% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.69B |
| Shares Change (YoY) | +53.94% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 50.47% |
| Owned by Institutions (%) | 2.85% |
| Float | 818.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.12 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.23 |
| EV / Sales | 20.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.13
| Current Ratio | 0.13 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -54.09 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -120.35% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 85,467 |
| Profits Per Employee | -187,267 |
| Employee Count | 15 |
| Asset Turnover | 0.83 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 76.06 |
| Average Volume (20 Days) | 5,721,635 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biolidics had revenue of SGD 1.28 million and -2.81 million in losses. Loss per share was -0.00.
| Revenue | 1.28M |
| Gross Profit | 579,000 |
| Operating Income | -2.98M |
| Pretax Income | -2.95M |
| Net Income | -2.81M |
| EBITDA | -2.97M |
| EBIT | -2.98M |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 166,000 in cash and 2.43 million in debt, giving a net cash position of -2.27 million or -0.00 per share.
| Cash & Cash Equivalents | 166,000 |
| Total Debt | 2.43M |
| Net Cash | -2.27M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -2.81M |
| Book Value Per Share | -0.00 |
| Working Capital | -2.80M |
Cash Flow
| Operating Cash Flow | -2.03M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 45.16%, with operating and profit margins of -232.06% and -219.11%.
| Gross Margin | 45.16% |
| Operating Margin | -232.06% |
| Pretax Margin | -230.03% |
| Profit Margin | -219.11% |
| EBITDA Margin | -231.59% |
| EBIT Margin | -232.06% |
| FCF Margin | n/a |
Dividends & Yields
Biolidics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -53.94% |
| Shareholder Yield | -53.94% |
| Earnings Yield | -26.99% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biolidics has an Altman Z-Score of -217.72. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -217.72 |
| Piotroski F-Score | n/a |